https://orcid.org/0000-0002-7413-2773
About the Authors
- Darrell Pilling
-
Roles Conceptualization, Data curation, Formal analysis, Visualization, Writing – original draft, Writing – review & editing
* E-mail: dpilling@bio.tamu.edu (DP); rgomer@tamu.edu (RHG)
Affiliation Department of Biology, Texas A&M University, College Station, Texas, United States of America
- Trevor C. Martinez
-
Roles Formal analysis, Investigation, Visualization, Writing – review & editing
Affiliation Department of Biology, Texas A&M University, College Station, Texas, United States of America
- Richard H. Gomer
-
Roles Conceptualization, Formal analysis, Investigation, Visualization, Writing – original draft, Writing – review & editing
* E-mail: dpilling@bio.tamu.edu (DP); rgomer@tamu.edu (RHG)
Affiliation Department of Biology, Texas A&M University, College Station, Texas, United States of America
Competing Interests
RHG is a scientific founder of Prosia Therapies, an early-stage company developing NEU3 inhibitors as therapeutics for pulmonary fibrosis. Texas A&M University has published patent applications on the use of sialidase inhibitors (United States Patent Application 20190201485) to regulate fibrosis. DP and RHG are inventors on pending patent applications for the use of sialidase inhibitors as anti-inflammatory, anti-fibrotic, and/or anti-obesity compounds.